Survival analysis of XXXX .

@entity1 @entity2057
PURPOSE: The life expectancy of @entity1 with @entity2057 ( @entity2057 ) type I is generally considered to be less than 2 years. Recently, with the introduction of proactive treatments, a longer survival and an improved survival rate have been reported. In this study, we analyzed the natural courses and survival statistics of @entity2057 @entity1 and compared the clinical characteristics of the @entity1 based on their survival periods. METHODS: We reviewed the medical records of 14 pediatric @entity1 diagnosed with @entity2057 during a 9-year period. We examined the demographic and clinical characteristics of these @entity1 , calculated their survival probabilities, and plotted survival curves as on the censoring date, January 1, 2010. We also compared the characteristics of the @entity1 who died before the age of 24 months (early-death, ED group) and those who survived for 24 months or longer (long-survival, LS group). RESULTS: The mean survival time was 22.8  2.0 months. The survival probabilities at 6 months, 12 months, 18 months, 24 months, and 30 months were 92.9%, 92.9%, 76.0%, 76.0%, and 65.1%, respectively. Birth weight was the only factor that showed a statistically significant difference between the ED and LS groups (P=0.048). CONCLUSION: In this study, the survival probabilities at 2 years were far greater than expected. Because of the limited number of @entity1 and information in this study, the contribution of improved supportive care on longer survival could not be clarified; this may be elucidated in larger cohort studies.
